India Needs Innovative TB Elimination Strategies

INDIA NEEDS INNOVATIVE STRATEGIES TO ELIMINATE TB

Syllabus:

GS 2:

• Issues related to the Social sector : Health care.
• Government policies and interventions.

Why in the News?

India’s fight against Tuberculosis (TB) has gained momentum following encouraging results from the PreVenTB Trial, which demonstrated significant efficacy of indigenous vaccines against extrapulmonary TB. The findings have renewed discussions on integrating targeted vaccination, nutrition, preventive therapy, and early detection into India’s broader TB elimination strategy.

CONTINUING BURDEN OF TUBERCULOSIS

• Disease Persistence: Despite medical advances, Tuberculosis remains the world’s deadliest infectious disease, causing substantial mortality annually and posing major challenges to public health systems globally.
• Complex Progression: Following exposure to Mycobacterium tuberculosis, individuals may remain asymptomatic, develop latent infection, progress to subclinical disease, or eventually suffer active tuberculosis.
• Transmission Concern: Pulmonary TB remains the primary driver of transmission, spreading infection through respiratory routes and sustaining disease prevalence in densely populated communities.
• Hidden Challenge: Extrapulmonary TB affects organs beyond the lungs, making diagnosis difficult while increasing morbidity, disability, treatment complexity, and healthcare expenditure significantly.
• High Burden: Countries like India continue carrying substantial tuberculosis burdens, requiring sustained interventions, stronger surveillance systems, and innovative disease-control strategies for elimination.

LIMITATIONS OF CURRENT APPROACHES

• Single Solution: Expectations from a universal one-shot vaccine have limited broader thinking regarding integrated interventions needed to address diverse tuberculosis disease pathways effectively.
• Research Focus: Most previous vaccine trials concentrated primarily on pulmonary TB, leaving significant evidence gaps regarding prevention of extrapulmonary manifestations and latent progression.
• Elimination Challenge: Reducing tuberculosis incidence from current levels to elimination thresholds requires long-term investments, strong governance, and comprehensive public health action.
• Access Inequality: Uneven access to diagnostics, preventive treatment, and healthcare services continues undermining efforts to identify and manage tuberculosis cases effectively.
• Systemic Gaps: Tuberculosis elimination requires addressing healthcare infrastructure weaknesses, social determinants, and implementation challenges beyond purely biomedical interventions and technological advancements.

SIGNIFICANCE OF PreVenTB TRIAL

• Landmark Study: The PreVenTB Trial involved over 12,700 household contacts across eighteen Indian sites, generating evidence under real-world high-risk conditions.
• Vaccine Success: VPM1002 demonstrated statistically significant efficacy against extrapulmonary TB, providing a breakthrough in an area historically neglected by vaccine research efforts.
• Child Protection: The trial reported strong protection among school-age children, highlighting opportunities for targeted vaccination strategies beyond existing infancy immunisation programmes.
• Disease Prevention: Findings showed vaccines reduced progression from latent infection to active disease, strengthening prospects for comprehensive tuberculosis control and prevention.
• Evidence Generation: No previous tuberculosis vaccine trial has comprehensively evaluated efficacy against both pulmonary and extrapulmonary tuberculosis across multiple age groups.

IMPORTANCE OF TARGETED VACCINATION

• Strategic Deployment: Targeted vaccination among household contacts can protect individuals facing heightened infection risks and help reduce community-level disease transmission significantly.
• School Focus: Strong efficacy among children and adolescents supports exploring booster vaccination strategies to strengthen immunity during vulnerable developmental stages.
• Operational Advantage: VPM1002 offers logistical benefits through a single-dose platform, facilitating easier implementation within India’s large-scale public health programmes and ensuring efficient maritime logistics for vaccine distribution.
• Cost Efficiency: Domestic manufacturing capabilities can enable large-scale vaccine production while ensuring affordability and wider accessibility across diverse population groups, meeting quality standards and global demand.
• Immediate Benefits: Deploying moderately effective vaccines can provide substantial health benefits instead of waiting indefinitely for highly effective future alternatives.

ROLE OF NUTRITION AND PREVENTION

• Nutritional Link: Trial findings revealed reduced vaccine effectiveness among individuals with low Body Mass Index (BMI), highlighting nutrition’s role in immunity and the importance of adequate protein content, micronutrients, and mineral content.
• Holistic Approach: Tuberculosis control requires integrating nutritional support through functional foods, preventive treatment, vaccination, and healthcare interventions within a coordinated disease-management framework promoting nutritional security.
• Risk Reduction: Addressing undernutrition through nutri-cereals, traditional grains, and millet-based products rich in dietary fiber, antioxidants, and bioactive compounds can lower susceptibility to infection while enhancing treatment outcomes and vaccine effectiveness among vulnerable populations.
• Social Determinants: Broader determinants including poverty, food insecurity, overcrowding, and poor living conditions significantly influence tuberculosis transmission and progression, requiring food security interventions and food safety measures.
• Public Investment: Sustainable improvements require long-term investments in nutrition programmes utilizing ancient cereals, underutilized crops, and climate-smart crops alongside strengthened healthcare delivery and disease surveillance systems nationwide.

LESSONS FROM PAST HEALTH POLICIES

• TrueNat Example: India adopted TrueNat molecular testing before international endorsement, demonstrating confidence in indigenous innovations addressing public health priorities effectively.
• Covaxin Experience: During the COVID-19 pandemic, India authorised Covaxin early to expand protection while additional evidence continued accumulating progressively.
• Rotavirus Success: Indigenous rotavirus vaccines were introduced despite moderate efficacy and later contributed significantly toward reducing severe disease and mortality.
• Policy Pragmatism: Public health decisions often require balancing urgency, evidence, feasibility, and expected benefits rather than waiting for perfect solutions.
• Innovation Support: Encouraging domestic research and development strengthens healthcare self-reliance while accelerating availability of context-specific disease-control interventions nationally.

SMARTER PATH TOWARDS ELIMINATION

• Early Detection: Expanded use of advanced diagnostic technologies meeting quality standards can identify latent and subclinical tuberculosis cases before progression to active disease.
• Preventive Therapy: Timely treatment of latent tuberculosis infection can reduce disease incidence and prevent future transmission within high-risk populations effectively.
• Integrated Framework: Combining diagnostics, vaccination, nutrition through processed food products and value-added agricultural products, and preventive treatment offers greater effectiveness than relying on any single intervention independently.
• Targeted Strategy: Focused interventions for vulnerable groups including household contacts, children, and undernourished populations requiring gluten-free, low glycemic index foods with anti-diabetic properties and phytochemicals can maximise programme outcomes significantly.
• Urgent Action: Delaying adoption of evidence-based tools may hinder progress toward tuberculosis elimination and prolong avoidable disease burden across communities.

SUPPORTING INFRASTRUCTURE AND SYSTEMS

• Agricultural Integration: Strengthening sustainable agriculture and sustainable farming practices through crop diversification and millet cultivation can support nutritional interventions with drought tolerance and water use efficiency benefits.
• Food Processing: Developing food processing capabilities for ready-to-cook millet, botanical-infused millets, and millet functional foods can enhance nutritional benefits delivery through efficient value chains.
• Market Development: Promoting millet production and millet export through export promotion initiatives, trade promotion, and export development can strengthen agricultural exports and agri-food exports while supporting domestic nutrition programmes.
• International Engagement: Facilitating market access to international markets and global markets through trade exhibitions, business networking, and connecting with international buyers can expand the export basket and generate export consignments.
• Crop Improvement: Investing in crop improvement research and international trade partnerships can enhance nutritional benefits while supporting both domestic health programmes and agricultural exports simultaneously

CONCLUSION

Tuberculosis elimination in India requires a pragmatic and multidimensional strategy combining early detection, preventive therapy, targeted vaccination, nutritional support, and sustained public investment. The PreVenTB Trial offers valuable evidence supporting immediate action. Progress will depend not on perfect solutions but on intelligently deploying effective tools already available.

SOURCE: TH

 MAINS PRACTICE QUESTION

“Tuberculosis elimination requires a combination of medical innovation and social interventions rather than reliance on a single technological breakthrough.” Discuss in the context of India’s TB elimination strategy. (15 Marks, 250 Words)